Pramlintide FAQ: common questions answered
A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.
Also called: Symlin, SymlinPen, Pramlintide acetate, AC137, AC-0137, Tripro-amylin.
Amylin analogues · Short-acting amylin receptor agonist · Evidence: Approved drug.
- Is Pramlintide FDA-approved? Yes: Symlin / SymlinPen (add-on for type 1 or type 2 diabetes using mealtime insulin with inadequate control despite optimized insulin.). Approved 2005-03-16. All products are listed Discontinued; manufacture notices date to 2025-10-27. These listings do not establish real-time inventory or a safety-related approval withdrawal.
- How do people take it? Under the skin, immediately before each major meal. Source: drug label.
- What's the difference between Pramlintide and Semaglutide? Pramlintide: a diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued. Semaglutide: a GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter. Why people pair them: two published cases combined fullness pathways for weight loss in type 1 diabetes and obesity.
- Can I take it with Semaglutide? Two published cases combined fullness pathways for weight loss in type 1 diabetes and obesity. No randomized trial of this pramlintide pair was located; nausea and insulin changes need close attention. Source: clinician-published. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). No pramlintide-specific ruling found. The 2026 list does not name it; S0 depends on current approval and S4.4.2 covers accompanying insulin.
- How do I store it once opened? After first use: refrigerate or keep at no more than 30°C; discard after 30 days even if refrigerated.
Related to Pramlintide
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
- CagriSema: An unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA: SYMLIN, NDA 021332, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.